Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | DRD3 | P35462 | 4/20 | 0.42 |
| ▸ | DRD1 | P21728 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 2/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31051933 | 0.87 | DRD2 (0.42) | DRD2DRD3DRD1HTR2ASIGMAR1 | |
| SCHEMBL31051780 | 0.86 | ADRB1 (0.38) | DRD2DRD3DRD1HTR2ASIGMAR1 | |
| SCHEMBL31051972 | 0.86 | DRD2 (0.41) | DRD2DRD3DRD1HTR2ASIGMAR1 | |
| SCHEMBL31051792 | 0.86 | ADRB1 (0.38) | DRD2DRD3DRD1HTR2ASIGMAR1 | |
| SCHEMBL31051794 | 0.86 | ADRB1 (0.38) | DRD2DRD3DRD1HTR2ASIGMAR1 | |
| SCHEMBL31052229 | 0.86 | DRD2 (0.41) | DRD2DRD3DRD1HTR2ASIGMAR1 | |
| SCHEMBL31051827 | 0.80 | DRD2 (0.59) | DRD2DRD3DRD1HTR2ASIGMAR1 | |
| SCHEMBL31052244 | 0.78 | DRD2 (0.65) | DRD2DRD3DRD1HTR2ASIGMAR1 | |
| SCHEMBL31052214 | 0.77 | ADRB1 (0.63) | ADRB1HTR1A | |
| SCHEMBL31051890 | 0.73 | DRD2 (0.42) | DRD2DRD3DRD1HTR2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678188-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING, OR MANAGING BILIRUBIN-INDUCED NEUROLOGICAL DYSFUNCTION, PSYCHIATRIC DISORDERS ASSOCIATED WITH JAUNDICE, OR PSYCHIATRIC DISORDERS CAUSED BY BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE GENE MUTATIONS | Ohnishi, Arata (JP) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024185842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING, OR MANAGING BILIRUBIN-INDUCED NEUROLOGICAL DYSFUNCTION, PSYCHIATRIC DISORDERS ASSOCIATED WITH JAUNDICE, OR PSYCHIATRIC DISORDERS CAUSED BY BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE GENE MUTATIONS | 国立大学法人島根大学 | 2024-09-12 | — | — | WO | disclosed |